Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders and proceeding down the body and into the limbs.

Extra-skeletal bone formation causes progressive loss of mobility as the joints become affected. Inability to fully open the mouth may cause difficulty in speaking and eating. Over time, people with this disorder may experience malnutrition due to their eating problems. They may also have breathing difficulties as a result of extra bone formation around the rib cage that restricts expansion of the lungs.

Any trauma to the muscles of an individual with fibrodysplasia ossificans progressiva, such as a fall or invasive medical procedures, may trigger episodes of muscle swelling and inflammation (myositis) followed by more rapid ossification in the injured area. Flare-ups may also be caused by viral illnesses such as influenza.

People with fibrodysplasia ossificans progressiva are generally born with malformed big toes. This abnormality of the big toes is a characteristic feature that helps to distinguish this disorder from other bone and muscle problems. Affected individuals may also have short thumbs and other skeletal abnormalities.

**Frequency**

Fibrodysplasia ossificans progressiva is a very rare disorder, believed to occur in approximately 1 in 2 million people worldwide. Several hundred cases have been reported.

**Causes**

Mutations in the *ACVR1* gene cause fibrodysplasia ossificans progressiva.

The *ACVR1* gene provides instructions for producing a member of a protein family called bone morphogenetic protein (BMP) type I receptors. The ACVR1 protein is found in many tissues of the body including skeletal muscle and cartilage. It helps to control the growth and development of the bones and muscles, including the gradual replacement of cartilage by bone (ossification) that occurs in normal skeletal maturation from birth to young adulthood.

Researchers believe that a mutation in the *ACVR1* gene may change the shape of the receptor under certain conditions and disrupt mechanisms that control the receptor's activity. As a result, the receptor may be constantly turned on (constitutive activation). Constitutive activation of the receptor causes overgrowth of bone and cartilage and
fusion of joints, resulting in the signs and symptoms of fibrodysplasia ossificans progressiva.

Inheritance Pattern
This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

Most cases of fibrodysplasia ossificans progressiva result from new mutations in the gene. These cases occur in people with no history of the disorder in their family. In a small number of cases, an affected person has inherited the mutation from one affected parent.

Other Names for This Condition

- Myositis Ossificans
- Myositis ossificans progressiva
- Progressive myositis ossificans
- progressive ossifying myositis

Diagnosis & Management

Genetic Testing Information
- What is genetic testing?
  /primer/testing/genetictesting
- Genetic Testing Registry: Progressive myositis ossificans

Research Studies from ClinicalTrials.gov
- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22fibrodysplasia+ossificans+progressiva%22+OR+%22Myositis+Ossificans%22

Additional Information & Resources

Health Information from MedlinePlus
- Health Topic: Bone Diseases
  https://medlineplus.gov/bonediseases.html
- Health Topic: Muscle Disorders
  https://medlineplus.gov/muscledisorders.html
- Health Topic: Myositis
  https://medlineplus.gov/myositis.html
Genetic and Rare Diseases Information Center

- Fibrodysplasia ossificans progressiva
  https://rarediseases.info.nih.gov/diseases/6445/fibrodysplasia-ossificans-progressiva

Educational Resources

- Johns Hopkins University: Skeletal Dysplasias
  https://www.hopkinsmedicine.org/healthlibrary/conditions/adult/orthopaedic_disorders/orthopedic_disorders_22,skeletal dysplasia

- MalaCards: fibrodysplasia ossificans progressiva
  https://www.malacards.org/card/fibrodysplasia_ossificans_progressiva

- Orphanet: Fibrodysplasia ossificans progressiva
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=337

- UCSF Children's Hospital
  https://www.ucsfbenioffchildrens.org/conditions/fibrodysplasia_ossificans_progressiva/

Patient Support and Advocacy Resources

- International Fibrodysplasia Ossificans Progressiva Association
  https://www.ifopa.org/

- National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/fibrodysplasia-ossificans-progressiva/

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Myositis+Ossificans%5BMAJ%5D%29+AND+%28fibrodysplasia+ossificans+progressiva%5BTIAB%5D%29+AND+english%5BLa%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
  http://omim.org/entry/135100

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12672843

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12804980
OMIM: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
http://omim.org/entry/135100

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16753021

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11521229

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17572636

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17477807

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17351709

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17516498

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12616078

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15232462

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16642017

Reprinted from Genetics Home Reference:

Reviewed: August 2007
Published: October 30, 2018